Question explored with the scientific record
Is hormone replacement therapy risky for women who start it within ten years of menopause?
The short version: starting within ten years of menopause is the safest window for hormones, but "safest" is not "risk-free," and the breast cancer signal is real.
The timing question has a clear answer in this evidence. A large analysis of over a million women found that starting hormones before or soon after menopause raised breast cancer risk more than starting later [3]. The cardiovascular picture splits by regimen and route. A 2015 review of 19 trials found younger women had fewer deaths and fewer heart attacks on hormones, but more blood clots [4]. The 2026 review found early initiation may cut mortality and cardiovascular events, while late initiation raised stroke risk [6]. Transdermal estrogen looks safer than oral for clots and stroke [5].
| Outcome | Early start (within 10 yrs) | Notes |
|---|---|---|
| Deaths (younger women) | 6 fewer per 1,000 users | RR 0.70 [4] |
| Heart disease | 8 fewer cases per 1,000 | RR 0.52 [4] |
| Blood clots | 5 extra cases per 1,000 | RR 1.74 [4] |
| Breast cancer, estrogen+progestin | Higher risk, rises per year of use | HR 1.44 [2] |
| Breast cancer, estrogen alone | Lower risk in women without a uterus | HR 0.71 [1] |
The breast cancer risk is not trivial. Estrogen plus progestin raised invasive breast cancer and deaths from it in the WHI trial [1], and a 2024 Norwegian cohort found risk climbing about 4% per year of use [2]. Estrogen alone, for women who had a hysterectomy, went the other way and reduced breast cancer [1]. The 2015 Cochrane review numbers come from trials that were not powered to detect rare events, so treat the cardiovascular benefit as suggestive, not settled [4][5].
My call: for a woman within ten years of menopause with bothersome symptoms, the balance favors hormones, especially transdermal estrogen, but the combined-pill breast cancer signal is real and should be weighed against her own risk. Confidence: moderate.
Sources used 6
-
Menopausal hormone therapy and breast cancer mortality: clinical implications
Combination menopausal hormone therapy with estrogen plus progestin increases breast cancer incidence and mortality and impairs detection, while estrogen alone reduces breast cancer incidence and mortality in women with prior hysterectomy, informing nuanced clinical use.
DOI: 10.1177/2042098614568300 -
Menopausal hormone therapy and incidence, mortality, and survival of breast cancer subtypes: a prospective cohort study
Current estrogen-progestin therapy was associated with increased incidence and mortality of overall and luminal A-like breast cancer, but not worse overall survival after diagnosis; pre-diagnostic use was associated with better triple-negative survival.
DOI: 10.1186/s13058-024-01897-4 -
Breast Cancer Risk in Relation to the Interval Between Menopause and Starting Hormone Therapy
This study investigates the relationship between the timing of hormone therapy initiation relative to menopause and breast cancer risk, finding that starting therapy before or soon after menopause significantly increases risk compared to starting later.
DOI: 10.1093/jnci/djq527 -
Hormone therapy and cardiovascular disease – are we back to the beginning?
This paper reviews the updated Cochrane Review on menopause hormone therapy (MHT) and its effects on cardiovascular disease, highlighting the differing impacts based on the timing of therapy initiation relative to menopause.
DOI: 10.3109/13697137.2015.1057958 -
The safety of oral versus transdermal estrogen
This Practice Pearl compares safety of oral versus transdermal estrogen, concluding that transdermal estrogen has lower VTE, stroke, and cardiovascular risk in high-risk women, while average-risk younger postmenopausal women have not shown increased risk with low-dose oral estro…
DOI: 10.1097/gme.0000000000001636 -
Cardiovascular risk in hormone replacement therapy
Cardiovascular risk from hormone replacement therapy varies with timing relative to menopause, dosage, and administration route, with early initiation within 10 years potentially reducing mortality and cardiovascular events while late initiation increases ischemic stroke risk; p…
DOI: 10.4081/btvb.2026.411